Ramucirumab & Docetaxel efficacy study in metastatic non-small cell lung cancer after failure of immunotherapy
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer